Liver transplantation in Australia and New Zealand

Liver Transplantation

Volumn 22, Issue 6, 2016, Pages 830-838

  McCaughan, Geoffrey W ^a,b   Munn, Stephen R ^c,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; CADAVER DONOR; CLINICAL RESEARCH; FUTUROLOGY; HEALTH CARE ACCESS; HEALTH CARE NEED; HISTORY; HOSPITAL ADMISSION; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; NEW ZEALAND; ORGAN DONOR; PRIORITY JOURNAL; REGISTER; RESOURCE ALLOCATION; ADULT; CHILD; DONOR; END STAGE LIVER DISEASE; EPIDEMIOLOGY; INDIGENOUS HEALTH CARE; INTERNATIONAL COOPERATION; LIVER FAILURE, ACUTE; MORTALITY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRANSPLANTATION; TRENDS;

ADULT; AUSTRALIA; CHILD; END STAGE LIVER DISEASE; HEALTH SERVICES, INDIGENOUS; HUMANS; INTERNATIONAL COOPERATION; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; NEW ZEALAND; REGISTRIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; WAITING LISTS;

EID: 84969940712     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24446     Document Type: Article

References (17)

1. Australia and New Zealand Liver Transplant Registry. www.anzltr.org. Accessed April 4, 2016.
2. The Transplantation Society of Australia and New Zealand. http://www.tsanz.com.au/organallocationprotocols/index.asp. Accessed April 4, 2016.
3. O'Grady JG, Alexander GJ, Hayllar KM, Williams R,. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-445.
4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al., Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
5. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
6. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al., A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
7. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW,; for Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
8. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomised study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2009; 48: 1460-1466.
9. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW,. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274.
10. Chen JW, Kow L, Verran DJ, McCall JL, Munn S, Balderson GA, et al., Poorer survival in patients whose explanted hepatocellular carcinoma (HCC) exceeds Milan or UCSF Criteria. An analysis of liver transplantation in HCC in Australia and New Zealand. HPB (Oxford) 2009; 11: 81-89.
11. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al.,; for Australian and New Zealand Liver Transplant Clinical Study Group. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003; 9: 339-347.
12. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW,. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006; 144: 239-248.
13. Crawford DH, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, et al., Patient and graft survival after liver transplantation for hereditary hemochromatosis: implications for pathogenesis. Hepatology 2004; 39: 1655-1662.
14. Chinnaratha MA, Chelvaratnam U, Stuart KA, Strasser SI, McCaughan GW, Gow P, et al.,; for Australia and New Zealand Liver Transplant Clinical Study Group. Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders. Liver Transpl 2014; 20: 798-806.
15. Verran DJ, Mulhearn MH, Dilworth PJ, Balderson GA, Munn S, Chen JW, et al., Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. Med J Aust 2013; 199: 610-612.
16. McCaughan GW, Shackel NA, Strasser SI, Dilworth P, Tang P,; for Australian and New Zealand Liver Transplant Study Group. Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark. Liver Transpl 2010; 16: 130-137.
17. Adams LA, Arauz O, Angus PW, Sinclair M, MacDonald GA, Chelvaratnam U, et al.,; for Australian New Zealand Liver Transplant Study Group. The additive impact of pre-liver transplant metabolic factors on survival post-liver transplant. J Gastroenterol Hepatol 2015; doi: 10.1111/jgh.13240.